Company intelligence / Profile preview

Fangzhou

Guangzhou, Guangdong, Chinapages.cs.wisc.edu ↗

Ownership: Private
Development stage: Other

Overview

Fangzhou is China’s leading online chronic disease management platform. It delivers tailored medical care and precision medicine solutions through its proprietary H2H Smart Healthcare Innovation Platform. The company leverages advanced AI models for patient engagement, chronic disease management, medication delivery, and physician support. As of December 2024, it serves over 49 million registered users and more than 223,000 physicians across China. Its technology has been recognized as a premier high-tech product in Guangdong Province.

Therapeutic areas: EndocrinologyOther
Modalities: Digital health platformsAI-driven healthcare deliveryOnline prescription & medication fulfillment
Industry: Non-Academic Healthcare

Partnerships

Tencent HealthTencent Cloud

Beyond the preview

Go deeper on Fangzhou.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fangzhou.

Explore the full profile